Journal article
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial
Abstract
BACKGROUND: l-asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered intramuscularly. Pegylated Escherichia coli asparaginase (PEG-asparaginase) has a longer half-life and is potentially less immunogenic than the native Escherichia coli (E coli) preparation, and can be more feasibly administered intravenously. The aim of the Dana-Farber Cancer Institute Acute Lymphoblastic …
Authors
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA
Journal
The Lancet Oncology, Vol. 16, No. 16, pp. 1677–1690
Publisher
Elsevier
Publication Date
December 2015
DOI
10.1016/s1470-2045(15)00363-0
ISSN
1470-2045
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, IntravenousAdolescentAge FactorsAntineoplastic AgentsAsparaginaseCanadaChildChild, PreschoolDisease-Free SurvivalEscherichia coliEscherichia coli ProteinsFemaleHumansInfantInjections, IntramuscularIntention to Treat AnalysisKaplan-Meier EstimateMalePolyethylene GlycolsPrecursor Cell Lymphoblastic Leukemia-LymphomaProportional Hazards ModelsQuality of LifeRisk FactorsSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited States